Intra-arterial Chemotherapy for Spinal Metastases (SIAC)
Metastatic malignant tumors comprise the vast majority of spinal tumors in adults. The most devastating complication of spinal metastatic disease (SMD) is invasion of the spinal canal and compression of the spinal cord or the nerve roots of the cauda equina, resulting in a clinical entity known as cord compression that manifests with progressive loss of motor function and sensation in the legs, as well as bladder and bowel incontinence.
The treatment of spinal metastases is mostly palliative with the goals of improving or maintaining neurologic function, achieving local tumor control, and spinal stability. Most patients with spinal metastatic disease are currently treated effectively with radiation therapy and/or surgery with good results. There are however certain limitations in the current treatment of SMD. Radiation therapy has two important limitations: 1) if the targeted SMD is in close proximity the spinal cord, delivery of high radiation doses is contraindicated as it may cause radiation-induced damage to the spinal cord (myelopathy, and 2) there is limit on the cumulative amount of radiation dose, which means that recurrent tumors may not be amenable to repeat radiation therapy. As far spinal surgery is concerned, the main limitation is that some patients are not fit for surgery because of medical co-morbidities.
This phase I clinical research trial will test the hypothesis that a new minimally invasive treatment called spinal intra-arterial chemotherapy (SIAC) can be safely applied in patients with SMD.
Drug: Melphalan (intra-arterial infusion)
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Selective Intra-arterial Chemotherapy in the Treatment Strategy of Metastatic Spinal Disease|
- Percentage of patients in whom intra-arterial chemotherapy is performed without severe complication. [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
- Change in spinal epidural tumor size as depicted on the MRI scans after treatment. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
|Study Start Date:||April 2012|
|Estimated Study Completion Date:||December 2018|
|Estimated Primary Completion Date:||April 2018 (Final data collection date for primary outcome measure)|
|Experimental: Selective intra-arterial chemotherapy||
Drug: Melphalan (intra-arterial infusion)
Patients will undergo a minimally invasive procedure called spinal angiography. This procedure will identify the arteries feeding the tumor causing cord compression and will determine whether chemotherapy can be safely infused.
The chemotherapy will be infused via a tiny soft plastic tube (called "microcatheter") at the tumor site over approximately 30 minutes.
The drug of choice is Melphalan (trade name Alkeran) at a maximum dose of 16mg/m2, adjusted for white cell count, platelet count and renal function.
We will perform up to three intra-arterial chemotherapy treatments in 3-6 week intervals, based on the results of complete blood counts.
To date, there is no effective systemic therapy for spinal metastases, and the goal of treatment is to achieve local control of the tumor. Despite advances in radiation therapy, there is still a subgroup of patients that cannot be effectively treated with radiation because of close proximity of the tumor to the spinal cord. In addition, in cases of recurrent tumors, some patients cannot be re-treated because they reached the maximum allowed radiation dose. Surgery is the alternative treatment for these patients, but some tumors do recur after surgery while some patients have comorbidities that make surgery a high-risk procedure.
Based on our prior experience with selective IA chemotherapy for the treatment of ocular retinoblastoma and the high local control rates achieved with selective IA injection of chemotherapy in recurrent limb melanoma (limb infusion and limb perfusion) we expect that spinal intra-arterial chemotherapy with selective injection of Melphalan in the arteries feeding the metastatic disease is feasible and safe and may prove beneficial in achieving local control of the spinal tumor, preventing neurological compromise from cord compression. This minimally invasive approach can be used in patients in whom radiation therapy and surgery are contra-indicated and essentially have no other treatment options.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01637766
|Contact: Athos Patsalides, MDfirstname.lastname@example.org|
|Contact: Kelly Hannsgen, RN||212-746-2821|
|United States, New York|
|Weill Cornell Medical College Department of Neurological Surgery||Recruiting|
|New York, New York, United States, 10065|
|Contact: Athos Patsalides, MD 212-746-2821 email@example.com|
|Principal Investigator: Athos Patsalides, MD|
|Sub-Investigator: Pierre Gobin, MD|
|Sub-Investigator: Mark Bilsky, MD|
|Sub-Investigator: Kimberly Salvaggio, NP|
|Principal Investigator:||Athos Patsalides, MD MPH||Weill Medical College of Cornell University|